| Name | IPI-3063 |
| Description | IPI-3063 is an effective and selective inhibitor of PI3K p110δ (IC50: 2.5 ± 1.2 nM). |
| In vitro | IPI-3063 is a p110δ selective compound with an IC50=0.1?nM in p110δ-specific cell-based assays and cellular IC50 values for the other class I PI3K isoforms are at least 1,000-fold higher (IC50=1901±1318 nM for p110α, IC50=102.8±35.7 nM for p110β, IC50=418.8±117.2 nM for p110γ). IPI-3063 is very effective in reducing p-AKT (significant effect at 1?nM) and it also decreases p-ERK1/2 with a significant effect at 10?nM. IPI-3063 is very effective, achieving a significant decrease in B cell survival when present at 10?nM and it also inhibits p110α, p110β, and p110γ (IC50s: 1171±533 nM, 1508±624 nM, and 2187±1529 nM, respectively). IPI-3063 effectively decreases mouse B cell proliferation, survival, and plasmablast differentiation while increasing antibody class switching to IgG1. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 83.33 mg/mL (182.94 mM)
|
| Keywords | Inhibitor | Phosphoinositide 3-kinase | inhibit | IPI3063 | IPI 3063 | IPI-3063 | PI3K |
| Inhibitors Related | Myricetin | Erucic acid | Sapanisertib | (2S,3R,4S)-4-Hydroxyisoleucine | Duvelisib (R enantiomer) hydrochloride | Isoprenaline hydrochloride | Quercetin | GDC0084 | Quercetin Dihydrate | Apilimod | LY294002 | Idelalisib |
| Related Compound Libraries | Highly Selective Inhibitor Library | Anti-Lung Cancer Compound Library | Neural Regeneration Compound Library | Bioactive Compound Library | Antidepressant Compound Library | Kinase Inhibitor Library | Inhibitor Library | Metabolism Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
United States
